SiBone
SIBN Healthcare Medical Devices
SiBone’s revenue for fiscal 2025 (year ended December 2025) was $200.9 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 15.2%, EPS grew 35.7%, free cash flow grew 60.1% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.
Follow SIBN
SiBone (SIBN) EV/Sales
As of 16 October 2026, SiBone (SIBN) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from 1.1× (January 2019) to 13.5× (May 2021); the current reading is higher than 35% of that period. That is above the Medical Devices industry median of 2.2× and in line with the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.7× | 30.85% |
| FY2024 | 2.8× | (42.14%) |
| FY2023 | 4.8× | 30.44% |
| FY2022 | 3.7× | (46.51%) |
| FY2021 | 6.9× | (29.34%) |
| FY2020 | 9.8× | 38.07% |
| FY2019 | 7.1× | 332.59% |
| FY2018 | 1.6× | (21.41%) |
| FY2017 | 2.1× | 0.00% |
| FY2016 | 2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.9× | 33.09% |
| Mar 2026 | 2.2× | (40.78%) |
| Dec 2025 | 3.7× | 34.62% |
| Sep 2025 | 2.7× | (27.61%) |
| 31 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AHCO AdaptHealth Corp. compare | 0.8× |
| INMD InMode Ltd. compare | 0.9× |
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| VREX VAREX IMAGING compare | 1.2× |
| QDEL QuidelOrtho Corporation compare | 1.4× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.5× |
| SIBN SiBone | 3.6× |
| BBNX Beta Bionics, Inc. compare | 4.6× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)